Glyprolins & PGP hybridsГлипролины
What is it?
A family record separating simple Pro/Gly peptides, PGP-containing hybrids and proposed protein-fragment lineages.
Research context
A family record separating simple Pro/Gly peptides, PGP-containing hybrids and proposed protein-fragment lineages.
What the studies found
review · 2005 · Secondary synthesis
Developer synthesis of glyprolin research
The developers described PGP-containing hybrid peptides as a way to combine regulatory activity with greater peptide stability. This historical framework does not transfer Semax or Selank outcomes to isolated PGP.
Limit: Review of a research program, not an independent trial.
Natural and hybrid ("chimeric") stable regulatory glyproline peptides. ↗animal · 2022
Rat transient middle cerebral artery occlusion; gene-expression assays
PGP and PGPL did not reproduce Semax’s gene-expression response after cerebral ischemia in rats. Most measured genes remained unchanged with the shorter peptides, underscoring that a shared PGP motif does not imply equivalent effects.
Limit: Preclinical findings do not establish human benefit or safety.
Insight into Glyproline Peptides' Activity through the Modulation of the Inflammatory and Neurosignaling Genetic Response Following Cerebral Ischemia-Reperfusion. ↗Selected findings, not a systematic review or a treatment recommendation. Combination and related-preparation results cannot be attributed to this compound alone. See each source for access status and remaining limitations.
- Working classification
- Peptide research family
- Research collection
- Neuropeptide research · editorial grouping
- Institutional provenance
- Not established for this compound record
- Last evidence review
- Full evidence review pending; source-check scope appears with each publication below.
What do we know?
- Human research
- —No human treatment trial assessed for this family
- Study methods
- —Member-specific studies; patents and archival leads identified separately
- Independent replication
- —Independent replication not established by the records collected here
- Source access
- —Primary abstracts, selected full texts, patents and explicit retrieval targets
- Safety evidence
- —Cell and animal effects do not establish human safety; analogues may differ
These are independent review fields, not a rating. Missing evidence in this starter does not mean no research exists.
Inside this research family
Grouping supports navigation. It does not imply equivalent composition, mechanisms, effectiveness or safety.
| Member | Identity | What the source supports |
|---|---|---|
| PGP / PG / GP | Linear glyprolin core | Historical developer literature motivates both stability and regulatory-function research. Natural and hybrid ("chimeric") stable regulatory glyproline peptides. ↗ |
| PGPL | Pro-Gly-Pro-Leu | Gene-expression effects after rat ischemia differed from Semax. |
| Semax / Selank | Distinct PGP-containing hybrid peptides | A shared tail is not evidence of interchangeable effects or source identity. Natural and hybrid ("chimeric") stable regulatory glyproline peptides. ↗ |
| Hydroxyproline sequences | GHyp, PHypG, GPHyp, GHypP, HypGP | Classification and collagen-fragment leads; individual Russian pharmacology requires source recovery. Original-source recovery pending |
Interpretation and open questions
Collagen/elastin breakdown is a proposed source for parts of this family; it is not proven provenance for every listed molecule.
The direct Semax/PGP/PGPL comparison is retained because its differences are more informative than a blanket claim of glyprolin neuroprotection.
Linked sources
Explore the research map and unresolved leads ↗
Natural and hybrid ("chimeric") stable regulatory glyproline peptides.
Ashmarin IP, Samonina GE, Lyapina LA, Kamenskii AA, Levitskaya NG, Grivennikov IA, Dolotov OV, Andreeva LA, Myasoedov NF · Pathophysiology : the official journal of the International Society for Pathophysiology
The developers described PGP-containing hybrid peptides as a way to combine regulatory activity with greater peptide stability. This historical framework does not transfer Semax or Selank outcomes to isolated PGP.
- Population / setting
- Developer synthesis of glyprolin research
- What was checked
- Primary publication metadata and indexed abstract checked via Europe PMC; full methodological review pending.
Limitations & review scope
- Review of a research program, not an independent trial.
- Specific peptide origin, metabolism and clinical claims require original-source confirmation.
Source checked 2026-10-05. This is a source-linked record, not a completed evidence review.
Insight into Glyproline Peptides' Activity through the Modulation of the Inflammatory and Neurosignaling Genetic Response Following Cerebral Ischemia-Reperfusion.
Stavchansky VV, Filippenkov IB, Remizova JA, Denisova AE, Mozgovoy IV, Gubsky LV, Myasoedov NF, Andreeva LA, Limborska SA, Dergunova LV · Genes
PGP and PGPL did not reproduce Semax’s gene-expression response after cerebral ischemia in rats. Most measured genes remained unchanged with the shorter peptides, underscoring that a shared PGP motif does not imply equivalent effects.
- Population / setting
- Rat transient middle cerebral artery occlusion; gene-expression assays
- What was checked
- Primary publication metadata and indexed abstract checked via Europe PMC; full methodological review pending.
Limitations & review scope
- Preclinical findings do not establish human benefit or safety.
- Indexed abstract reviewed; full methods and independent replication require appraisal.
Source checked 2026-10-05. This is a source-linked record, not a completed evidence review.